Ignite Creation Date:
2025-12-24 @ 11:55 PM
Ignite Modification Date:
2026-01-01 @ 1:13 PM
Study NCT ID:
NCT05215951
Status:
TERMINATED
Last Update Posted:
2025-10-15
First Post:
2021-11-15
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-01-19
Start Date Type:
ACTUAL
Primary Completion Date:
2023-03-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-03-09
Completion Date Type:
ACTUAL
First Submit Date:
2021-11-15
First Submit QC Date:
None
Study First Post Date:
2022-01-31
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-03-08
Results First Submit QC Date:
None
Results First Post Date:
2025-10-15
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-26
Last Update Post Date:
2025-10-15
Last Update Post Date Type:
ESTIMATED